Citi analyst Geoff Meacham raised the firm’s price target on Bristol Myers (BMY) to $60 from $53 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are “beatable” and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb Advances Repotrectinib Interaction Study: What Investors Should Know
- Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig
- Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
- Bristol Myers Squibb Advances Opdivo/Yervoy in China Mesothelioma Trial, Signaling New Oncology Upside
- Janux Therapeutics enters exclusive license agreement with Bristol Myers